These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38063420)

  • 41. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia.
    Grainger J; Bussel J; Tarantino M; Cooper N; Beam D; Despotovic J; Maschan A; Wang K; Eisen M; Bowers C
    Blood Adv; 2023 Feb; 7(3):396-405. PubMed ID: 35413092
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.
    Grainger JD; Kühne T; Hippenmeyer J; Cooper N
    Ann Hematol; 2021 Sep; 100(9):2143-2154. PubMed ID: 34308495
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy.
    Maitland HS
    Am J Case Rep; 2021 Dec; 22():e933788. PubMed ID: 34862358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia.
    Wang X; Bi H; Liu L; Liu Y; Yin L; Yao J; Yu J; Tao W; Wei Y; Li Y; Yin L; Mu H; Du Y; Zhou Z
    Platelets; 2023 Dec; 34(1):2271568. PubMed ID: 37941414
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
    Gilreath J; Lo M; Bubalo J
    Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study.
    Liu X; Bai Y; Wang T; Song Y; Sun F; Xia R; Zhu F; Ma J; Lu Q; Ye X; Zhan X; Li L; Guo X; Cheng S; Li Y; Guo Z; Chen Y; Qian S; Qin L; Zhang Q; Cao S; Yang R
    Platelets; 2023 Dec; 34(1):2157806. PubMed ID: 36597010
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia.
    Mingot-Castellano ME; Caparrós IS; Fernández F; Perera-Alvarez MDM; Jimenez-Bárcenas R; Casaus García A; González-Silva M; Yera-Cobo M; Nieto-Hernandez MM; Rodríguez-Fernandez MJ; Díaz-Canales D
    Blood Coagul Fibrinolysis; 2018 Jun; 29(4):374-380. PubMed ID: 29738335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives.
    Tsykunova G; Ghanima W
    Ther Clin Risk Manag; 2022; 18():273-286. PubMed ID: 35386180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.
    Yang R; Lin L; Yao H; Ji O; Shen Q
    Hematology; 2019 Dec; 24(1):290-299. PubMed ID: 30661482
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
    Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
    Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Generic romiplostim for children with persistent or chronic immune thrombocytopenia: Experience from a tertiary care centre in North India.
    Mareddy C; Kalra M; Sachdeva A
    Br J Haematol; 2022 Jun; 197(5):618-626. PubMed ID: 35467751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.
    Al-Samkari H; Kolb-Sielecki J; Safina SZ; Xue X; Jamieson BD
    Lancet Haematol; 2022 Mar; 9(3):e179-e189. PubMed ID: 35240074
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children.
    Ramaswamy K; Hsieh L; Leven E; Thompson MV; Nugent D; Bussel JB
    J Pediatr; 2014 Sep; 165(3):600-5.e4. PubMed ID: 24857517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia.
    Kuter DJ; Tarantino MD; Lawrence T
    Blood Rev; 2021 Sep; 49():100811. PubMed ID: 33781612
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
    Janssens A; Rodeghiero F; Anderson D; Chong BH; Boda Z; Pabinger I; Červinek L; Terrell DR; Wang X; Franklin J
    Ann Hematol; 2016 Jun; 95(7):1077-87. PubMed ID: 27130310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.